Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies
DF Quail, JA Joyce - Clinical Cancer Research, 2017 - aacrjournals.org
DF Quail, JA Joyce
Clinical Cancer Research, 2017•aacrjournals.orgTumor-associated macrophages (TAMs) are a major cellular component of numerous tumor
types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions
or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy.
Here, we review preclinical and clinical strategies to target macrophages in cancer and
discuss potential explanations for why some strategies are effective while other approaches
have shown limited success. Clin Cancer Res; 23 (4); 876–84.© 2016 AACR.
types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions
or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy.
Here, we review preclinical and clinical strategies to target macrophages in cancer and
discuss potential explanations for why some strategies are effective while other approaches
have shown limited success. Clin Cancer Res; 23 (4); 876–84.© 2016 AACR.
Abstract
Tumor-associated macrophages (TAMs) are a major cellular component of numerous tumor types. TAM-targeted therapies include depletion strategies, inhibiting their effector functions or reprogramming toward an antitumorigenic phenotype, with varying degrees of efficacy. Here, we review preclinical and clinical strategies to target macrophages in cancer and discuss potential explanations for why some strategies are effective while other approaches have shown limited success. Clin Cancer Res; 23(4); 876–84. ©2016 AACR.
aacrjournals.org